BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28342444)

  • 1. Acid Ceramidase Deficiency in Mice Results in a Broad Range of Central Nervous System Abnormalities.
    Sikora J; Dworski S; Jones EE; Kamani MA; Micsenyi MC; Sawada T; Le Faouder P; Bertrand-Michel J; Dupuy A; Dunn CK; Xuan ICY; Casas J; Fabrias G; Hampson DR; Levade T; Drake RR; Medin JA; Walkley SU
    Am J Pathol; 2017 Apr; 187(4):864-883. PubMed ID: 28342444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acid Ceramidase Deficiency in Mice Leads to Severe Ocular Pathology and Visual Impairment.
    Yu FPS; Sajdak BS; Sikora J; Salmon AE; Nagree MS; Gurka J; Kassem IS; Lipinski DM; Carroll J; Medin JA
    Am J Pathol; 2019 Feb; 189(2):320-338. PubMed ID: 30472209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spinal muscular atrophy-like phenotype in a mouse model of acid ceramidase deficiency.
    Nagree MS; Rybova J; Kleynerman A; Ahrenhoerster CJ; Saville JT; Xu T; Bachochin M; McKillop WM; Lawlor MW; Pshezhetsky AV; Isaeva O; Budde MD; Fuller M; Medin JA
    Commun Biol; 2023 May; 6(1):560. PubMed ID: 37231125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. rAAV-mediated over-expression of acid ceramidase prevents retinopathy in a mouse model of Farber lipogranulomatosis.
    Zhang H; Nagree MS; Liu H; Pan X; Medin JA; Lipinski DM
    Gene Ther; 2023 Apr; 30(3-4):297-308. PubMed ID: 35902747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic lung injury and impaired pulmonary function in a mouse model of acid ceramidase deficiency.
    Yu FPS; Islam D; Sikora J; Dworski S; Gurka J; López-Vásquez L; Liu M; Kuebler WM; Levade T; Zhang H; Medin JA
    Am J Physiol Lung Cell Mol Physiol; 2018 Mar; 314(3):L406-L420. PubMed ID: 29167126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acid ceramidase deficiency associated with spinal muscular atrophy with progressive myoclonic epilepsy.
    Gan JJ; Garcia V; Tian J; Tagliati M; Parisi JE; Chung JM; Lewis R; Baloh R; Levade T; Pierson TM
    Neuromuscul Disord; 2015 Dec; 25(12):959-63. PubMed ID: 26526000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic pathology and altered gene transcription in a murine model of acid ceramidase deficiency.
    Yu FPS; Molino S; Sikora J; Rasmussen S; Rybova J; Tate E; Geurts AM; Turner PV; Mckillop WM; Medin JA
    Lab Invest; 2019 Oct; 99(10):1572-1592. PubMed ID: 31186526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic ceramide accumulation leads to severe and varied pathological consequences.
    Alayoubi AM; Wang JC; Au BC; Carpentier S; Garcia V; Dworski S; El-Ghamrasni S; Kirouac KN; Exertier MJ; Xiong ZJ; Privé GG; Simonaro CM; Casas J; Fabrias G; Schuchman EH; Turner PV; Hakem R; Levade T; Medin JA
    EMBO Mol Med; 2013 Jun; 5(6):827-42. PubMed ID: 23681708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acid Sphingomyelinase Deficiency Ameliorates Farber Disease.
    Beckmann N; Becker KA; Kadow S; Schumacher F; Kramer M; Kühn C; Schulz-Schaeffer WJ; Edwards MJ; Kleuser B; Gulbins E; Carpinteiro A
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: identification of the first large deletion in ASAH1 gene.
    Alves MQ; Le Trionnaire E; Ribeiro I; Carpentier S; Harzer K; Levade T; Ribeiro MG
    Mol Genet Metab; 2013 Jul; 109(3):276-81. PubMed ID: 23707712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel V97G ASAH1 mutation found in Farber disease patients: unique appearance of the disease with an intermediate severity, and marked early involvement of central and peripheral nervous system.
    Chedrawi AK; Al-Hassnan ZN; Al-Muhaizea M; Colak D; Al-Younes B; Albakheet A; Tulba S; Kaya N
    Brain Dev; 2012 May; 34(5):400-4. PubMed ID: 21893389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acid Ceramidase Depletion Impairs Neuronal Survival and Induces Morphological Defects in Neurites Associated with Altered Gene Transcription and Sphingolipid Content.
    Kyriakou K; Lederer CW; Kleanthous M; Drousiotou A; Malekkou A
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease.
    Ramsubir S; Nonaka T; Girbés CB; Carpentier S; Levade T; Medin JA
    Mol Genet Metab; 2008 Nov; 95(3):133-41. PubMed ID: 18805722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ASAH1-related disorders: Description of 15 novel pediatric patients and expansion of the clinical phenotype.
    Mahmoud IG; Elmonem MA; Zaki MS; Ramadan A; Al-Menabawy NM; El-Gamal A; Mansour L; Issa MY; Abdel-Hamid MS; Abdel-Hady S; Khalifa I; Ibrahim A; Solyom A; Rolfs A; Selim L
    Clin Genet; 2020 Dec; 98(6):598-605. PubMed ID: 32875576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceramidases, roles in sphingolipid metabolism and in health and disease.
    Coant N; Sakamoto W; Mao C; Hannun YA
    Adv Biol Regul; 2017 Jan; 63():122-131. PubMed ID: 27771292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acid ceramidase deficiency: Farber disease and SMA-PME.
    Yu FPS; Amintas S; Levade T; Medin JA
    Orphanet J Rare Dis; 2018 Jul; 13(1):121. PubMed ID: 30029679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ASAH1 pathogenic variants associated with acid ceramidase deficiency: Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy.
    Elsea SH; Solyom A; Martin K; Harmatz P; Mitchell J; Lampe C; Grant C; Selim L; Mungan NO; Guelbert N; Magnusson B; Sundberg E; Puri R; Kapoor S; Arslan N; DiRocco M; Zaki M; Ozen S; Mahmoud IG; Ehlert K; Hahn A; Gokcay G; Torcoletti M; Ferreira CR
    Hum Mutat; 2020 Sep; 41(9):1469-1487. PubMed ID: 32449975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological manifestations of Farber disease in a new mouse model.
    Beckmann N; Kadow S; Schumacher F; Göthert JR; Kesper S; Draeger A; Schulz-Schaeffer WJ; Wang J; Becker JU; Kramer M; Kühn C; Kleuser B; Becker KA; Gulbins E; Carpinteiro A
    Biol Chem; 2018 Sep; 399(10):1183-1202. PubMed ID: 29908121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical presentation of infantile-onset farber disease with novel ASAH1 mutations.
    Kim SY; Choi SA; Lee S; Lee JS; Hong CR; Lim BC; Kang HJ; Kim KJ; Park SH; Choi M; Chae JH
    Am J Med Genet A; 2016 Nov; 170(11):3023-3027. PubMed ID: 27411168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acid Ceramidase Deficiency: Bridging Gaps between Clinical Presentation, Mouse Models, and Future Therapeutic Interventions.
    Kleynerman A; Rybova J; Faber ML; McKillop WM; Levade T; Medin JA
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.